期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

放疗联合唑来膦酸姑息性治疗骨转移癌86例疗效分析 被引量：5

下载PDF
导出
摘要 目的观察放疗联合唑来膦酸治疗骨转移癌的疗效。方法将骨转移癌患者随机分为放疗联合唑来膦酸治疗组和单纯放疗组,各43例,放疗40Gy/20次,唑来膦酸采用4mg静脉滴注,对两组疗效进行观察比较。结果治疗结束后3个月,联合治疗组疼痛缓解总有效率为88.4%,单纯放疗组为72.1%,差异具有显著性(P<0.05)。两组间不良反应发生率无显著差异(P>0.05)。结论放疗联合唑来膦酸治疗骨转移癌疗效确切,不良反应轻微,操作简便,值得临床推广。
作者 胡莉钧 李毅 聂斌
机构地区 常州市第二人民医院放疗科
出处 《中国医药指南》 2011年第16期99-100,共2页 Guide of China Medicine
关键词 骨转移癌 放射治疗 唑来膦酸 疼痛
分类号 R738.1 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1董梅,陈学鹏,冯奉仪.双膦酸盐治疗恶性肿瘤骨转移的研究进展[J].中华肿瘤杂志,2007,29(11):801-803. 被引量：8
  • 2Real C,Turkiewicz AM,Reale CA.Antalgic treatment of pain associated with bone metastases[J].Crit Rev Oncol Hernatol, 2001,37(1): 1-11.
  • 3谷铣之,殷蔚伯,刘泰福.肿瘤放射治疗学[M].4版.北京:中国协和医科大学出版社,2008:47.
  • 4Ferretti G,Fabi A,Carlini P, et al.Zoledronic-acid-induced circulating level modifications of angiogenic factors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients[J]. Oncology,2005,69(1):35-43.

二级参考文献21

  • 1Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun, 2005, 328:746-750.
  • 2Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory eytokines in metastatic breast cancer patients. Oncology, 2005, 69:35-43.
  • 3Clezardin P, Ebetino FH, Foumier PG. Bisphosphonates and cancerinduced bone disease: beyond their antireserptive activity. Cancer Res, 2005, 65:4971-4974.
  • 4Pavlakis N, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Svst Rew. 2005. CD003474.
  • 5Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol, 2004, 15:743-750.
  • 6Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain, 2004, 111:306-312.
  • 7Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol, 2004, 31:67-72.
  • 8Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin Pharmacother, 2004, 5: 2341-2350.
  • 9Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rew, 2005, 3:19-25.
  • 10Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int, 2005, 96:964-969.

共引文献50

同被引文献68

引证文献5

二级引证文献38

中国医药指南
2011年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部